Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HS-20093 for recurrent or refractory bone and soft tissue sarcoma
CTR20230946Phase 2Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan in bone cancer, soft tissue sarcoma (STS), sponsored by Hansoh Pharmaceutical Group. Started Jun 2023; status: active.
02
Drugs
risvutatug rezetecan
03
Conditions
bone cancersoft tissue sarcoma (STS)
Beyond the preview
Go deeper on CTR20230946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230946.